Skip to main content
. 2021 Feb;10(2):737–752. doi: 10.21037/tlcr-20-958

Figure 2.

Figure 2

Kaplan-Meier curves for progression-free survival (PFS) depending on KRAS mutational status (A), TP53 mutational status (B), KRAS subgroups (KRASG12C vs. KRASother (C) and KRAS/TP53 co-mutations (KRASG12C/TP53mut vs. KRASG12C/TP53wt vs. KRASother/TP53mut vs. KRASother/TP53wt (D).